IL217756A0 - Inhibitors of jnk - Google Patents

Inhibitors of jnk

Info

Publication number
IL217756A0
IL217756A0 IL217756A IL21775612A IL217756A0 IL 217756 A0 IL217756 A0 IL 217756A0 IL 217756 A IL217756 A IL 217756A IL 21775612 A IL21775612 A IL 21775612A IL 217756 A0 IL217756 A0 IL 217756A0
Authority
IL
Israel
Prior art keywords
jnk
inhibitors
Prior art date
Application number
IL217756A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL217756A0 publication Critical patent/IL217756A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL217756A 2009-08-10 2012-01-26 Inhibitors of jnk IL217756A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23252209P 2009-08-10 2009-08-10
PCT/EP2010/061476 WO2011018417A1 (en) 2009-08-10 2010-08-06 Inhibitors of jnk

Publications (1)

Publication Number Publication Date
IL217756A0 true IL217756A0 (en) 2012-03-29

Family

ID=42710723

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217756A IL217756A0 (en) 2009-08-10 2012-01-26 Inhibitors of jnk

Country Status (15)

Country Link
US (1) US8536172B2 (enExample)
EP (1) EP2464640A1 (enExample)
JP (1) JP5784604B2 (enExample)
KR (1) KR101506318B1 (enExample)
CN (1) CN102471319B (enExample)
AR (1) AR077820A1 (enExample)
AU (1) AU2010283769B2 (enExample)
BR (1) BR112012003059A2 (enExample)
CA (1) CA2768749A1 (enExample)
IL (1) IL217756A0 (enExample)
IN (1) IN2012DN01231A (enExample)
MX (1) MX2012001449A (enExample)
SG (1) SG178321A1 (enExample)
TW (1) TW201109336A (enExample)
WO (1) WO2011018417A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012155144A (ru) * 2010-06-04 2014-07-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
KR101862912B1 (ko) 2012-07-20 2018-05-30 클리브 바이오사이언스 인코포레이티드 (클리브) p97 복합체의 저해제로서의 축합된 피리미딘
US10624948B2 (en) * 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
DK3126352T3 (en) * 2014-04-04 2019-01-21 Syros Pharmaceuticals Inc CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7)
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
CN107567453A (zh) * 2015-03-13 2018-01-09 艾伯维公司 (吲唑‑4‑基)六氢吡咯并吡咯酮类及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5325783B2 (ja) * 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
JP5179509B2 (ja) * 2006-12-08 2013-04-10 エフ．ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用

Also Published As

Publication number Publication date
CA2768749A1 (en) 2011-02-17
US20110034470A1 (en) 2011-02-10
JP2013501746A (ja) 2013-01-17
CN102471319B (zh) 2014-06-18
CN102471319A (zh) 2012-05-23
AU2010283769A1 (en) 2012-02-09
WO2011018417A1 (en) 2011-02-17
US8536172B2 (en) 2013-09-17
MX2012001449A (es) 2012-03-26
AR077820A1 (es) 2011-09-28
AU2010283769B2 (en) 2015-09-17
TW201109336A (en) 2011-03-16
IN2012DN01231A (enExample) 2015-05-15
KR20120055645A (ko) 2012-05-31
BR112012003059A2 (pt) 2016-08-02
KR101506318B1 (ko) 2015-03-26
JP5784604B2 (ja) 2015-09-24
EP2464640A1 (en) 2012-06-20
SG178321A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
ZA201700326B (en) Inhibitors of beta-secretase
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
EP2438246A4 (en) CONSTRUCTION ASPECTS
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
ZA201206456B (en) Uses of dgati inhibitors
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL215645A0 (en) Inhibitors of cognitive decline
IL217833A0 (en) Inhibitors of cognitive decline
PL2506840T3 (pl) Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem
IL217756A0 (en) Inhibitors of jnk
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
EP2455089A4 (en) INHIBITOR OF RISE OF GIP IN BLOOD
EP2418208A4 (en) INHIBITOR OF INCREASE IN GIP RATE
IL208916A0 (en) Inhibitors of jnk
SI2411376T1 (sl) INHIBITORJI NF-kB
GB0914726D0 (en) Kinase inhibitors
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
GB0903651D0 (en) Inhibitors of glyoxalase
GB0803895D0 (en) Inhibitors of glyoxalase
GB0902661D0 (en) Inhibitors